Audrey Arzamendi, MD
Endocrinology, Diabetes & Metabolism · Walnut Creek, CANPI 1508159567
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,152 of the $12,724 with a category attached, or 71.9%. 42 manufacturers reported payments, led by Corcept Therapeutics at 32.4% of the total. Reporting peaked in 2019 at $5,082 and has fallen 96.1% since, to $200 in 2025.
Across 464 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$4K
- Novo Nordisk$1K
- Amgen$973
- Lilly USA, LLC$878
- Bayer$682
- Radius Health, Inc.$636
- plus $4K from 36 others
What the payments were for
- Consulting fees$2,42519%
- Travel & lodging$1,1359%
- Food & beverage$9,15272%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,724 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 213 | $337,053 |
| OzempicSemaglutide | 126 | $226,618 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 96 | $155,593 |
| TymlosAbaloparatide | 26 | $94,818 |
| JardianceEmpagliflozin | 63 | $91,035 |
| RybelsusSemaglutide | 30 | $68,419 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $34,291 |
| KerendiaFinerenone | 14 | $25,837 |
| Humalog Kwikpen U-100Insulin Lispro | 29 | $10,342 |
| SynthroidLevothyroxine Sodium | 76 | $7,791 |
| AfrezzaInsulin Regular, Human | 11 | $5,065 |
| TirosintLevothyroxine Sodium | 25 | $3,516 |
| Risedronate Sodium | 22 | $3,406 |
| LevoxylLevothyroxine Sodium | 34 | $2,227 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $1,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $878 | $337,053213 claims |
| Novo NordiskOzempic, Rybelsus | $1,316 | $295,037156 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $269 | $246,628159 claims |
| Radius Health, Inc.Tymlos | $636 | $94,81826 claims |
| BayerKerendia | $682 | $25,83714 claims |
| AbbVieSynthroid | $324 | $7,79176 claims |
| Mannkind CorporationAfrezza | $626 | $5,06511 claims |
| IBSA Pharma Inc.Tirosint | $82 | $3,51625 claims |
| PfizerLevoxyl | $19 | $2,22734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Walnut Creek
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.